NCT03412565 2025-04-29A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensJanssen Research & Development, LLCPhase 2 Completed265 enrolled 21 charts 3 FDA
NCT02415036 2022-10-17Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaDelcath Systems Inc.Phase 2 Terminated17 enrolled
NCT01660633 2020-04-21Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous TransplantationAcrotech Biopharma Inc.Phase 2 Completed61 enrolled
NCT00925782 2019-12-17PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous TransplantationAcrotech Biopharma Inc.Phase 2 Completed24 enrolled 10 charts
NCT00911859 2014-11-18A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma PatientsJanssen Research & Development, LLCPhase 2 Completed118 enrolled 16 charts
NCT01500161 2013-11-25Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTexas Oncology Cancer CenterPhase 2 Terminated1 enrolled
NCT00096083 2013-10-23Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerDelcath Systems Inc.Phase 2 Completed56 enrolled